









Markets
/
Stocks
/
nasdaq-rlyb
/

Rallybio Corp

RLYB

View Detailed Chart

0.535USD

+0.070+15.05%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

22.26MMarket Cap

LossP/E TTM



Rallybio Corp

0.535

+0.070+15.05%

Overview Company Financials

Financials

Intraday

30m

Today

+15.05%

5 Days

+7.28%

1 Month

+60.81%

6 Months

-38.40%

Year to Date

-44.27%

1 Year

-57.54%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 4 analysts

HOLD

Current Rating

1.000

Target Price

86.92%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Rallybio Corp

RLYB

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Ionis Pharmaceuticals Inc

IONS

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Buy

Sell(1)

Neutral(2)

Buy(9)

Indicators

Sell(0)

Neutral(2)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.002

Buy

RSI(14)

63.109

Neutral

STOCH(KDJ)(9,3,3)

65.893

Buy

ATR(14)

0.053

High Vlolatility

CCI(14)

84.211

Neutral

Williams %R

12.928

Overbought

TRIX(12,20)

1.444

Buy

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

0.491

Buy

MA10

0.496

Buy

MA20

0.460

Buy

MA50

0.386

Buy

MA100

0.407

Buy

MA200

0.676

Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical needs in the areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. It has two clinical-stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Its other product candidates include RLYB114, RLYB331 and ENPP1 Program. Its second C5 inhibitor, RLYB114, is a pegylated C5-targeted Affibody molecule with PK properties designed for the treatment of complement-mediated ophthalmic diseases. RLYB331 is for the treatment of severe anemia.

Ticker SymbolRLYB

CompanyRallybio Corp

CEODr. Stephen (Steve) Uden, M.D.

Websitehttps://rallybio.com/